Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers
暂无分享,去创建一个
L. Thurfjell | M. Mintun | W. Jagust | M. Pontecorvo | S. Landau | L. Thurfjell | S. Baker | R. Margolin | B. Thomas | W. J. Jagust | The Alzheimer’s Disease Neuroimaging Initiative | the Alzheimer’s Disease Neuroimaging Initiative | S. L. Baker | R. Margolin | S. M. Landau | B. A. Thomas | M. Schmidt | M. Mintun | M. Pontecorvo | M. Schmidt | Mark E. Schmidt
[1] L. Thurfjell,et al. Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease , 2009, Journal of Nuclear Medicine.
[2] C. Rowe,et al. Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[3] Christer Halldin,et al. Clinical Validation of 18F-AZD4694, an Amyloid-β–Specific PET Radioligand , 2012, The Journal of Nuclear Medicine.
[4] E. Salmon,et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.
[5] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[6] C. Rowe,et al. Imaging β-amyloid burden in aging and dementia , 2007, Neurology.
[7] R. Boellaard,et al. Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[8] Cindee M. Madison,et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.
[9] G. Linazasoro,et al. IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA , 2008, Neurology.
[10] M. Mintun,et al. Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods , 2013, The Journal of Nuclear Medicine.
[11] M. Modat,et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[12] M. Pontecorvo,et al. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[13] R. Coleman,et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.
[14] M. Mintun,et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline , 2012, Annals of neurology.
[15] W. Jagust,et al. Association of lifetime cognitive engagement and low β-amyloid deposition. , 2012, Archives of neurology.
[16] C. Rowe,et al. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.
[17] C. Rowe,et al. Characterization of PiB Binding to White Matter in Alzheimer Disease and Other Dementias , 2009, Journal of Nuclear Medicine.
[18] M. Mintun,et al. Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects , 2012, The Journal of Nuclear Medicine.
[19] H. Engler,et al. PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.
[20] James Robert Brašić,et al. In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.
[21] Jyrki Lötjönen,et al. Implementation and Validation of an Adaptive Template Registration Method for 18F-Flutemetamol Imaging Data , 2013, The Journal of Nuclear Medicine.
[22] M. Weiner,et al. Relationships between biomarkers in aging and dementia , 2009, Neurology.